Shengying Ye

Shengying Ye

Auto-generated profile, based on publicly available information

Shengying Ye

Pharmacy Department, The 983rd Hospital of The Joint Logistics Support Force of The Chinese People's Liberation Army, Tianjin, China

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Biosensors and Bioelectronics
Verified
Journal Article
Closed access
LYLijuan Yin
Lijuan Yin
SMShu li Man
Shu li Man
SYShengying Ye
Shengying Ye
GLGuozhen Liu
Guozhen Liu
Long MaLong Ma
Long Ma

14 March 2025 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
WPWeipan Peng
Weipan Peng
MSMengting Shi
Mengting Shi
BHBin Hu
Bin Hu
JJJingyu Jia
Jingyu Jia
XLXinyue Li
Xinyue Li
Long MaLong Ma
Long Ma
As promising noninvasive biomarkers, nucleic acids provide great potential to innovate cancer early detection methods and promote subsequent diagnosis to improve the survival rates of patient. Accurate, straightforward and sensitive detection of such nucleic acid-based cancer biomarkers in complex biological samples holds significant clinical importance. However, the low abundance creates huge challenges for their routine detection. As the next-generation diagnostic tool, Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein (Cas) with their high programmability, sensitivity, fidelity, single-base resolution, and precise nucleic acid positioning capabilities are extremely attractive for trace nucleic acid-based cancer biomarkers (NABCBs), permitting rapid, ultra-sensitive and specific detection. More importantly, by combing with nanotechnology, it can solve the long-lasting problems of poor sensitivity, accuracy and simplicity, as well as to achieve integrated miniaturization and portable point-of-care testing (POCT) detection. However, existing literature lacks specific emphasis on this topic. Thus, we intend to propose a timely one for the readers. This review will bridge this gap by providing insights for CRISPR/Cas-based nano-biosensing development and highlighting the current state-of-art, challenges, and prospects. We expect that it can provide better understanding and valuable insights for trace NABCBs detection, thereby facilitating advancements in early cancer screening/detection/diagnostics and win practical applications in the foreseeable future.

7 October 2023 in Trends in Biotechnology
Verified
Journal Article
Closed access
YLYaru Li
Yaru Li
JJJingyu Jia
Jingyu Jia
SMShuli Man
Shuli Man
SYShengying Ye
Shengying Ye
Long MaLong Ma
Long Ma

16 January 2026 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
NZNing Zhang
Ning Zhang
CTCan Tang
Can Tang
SZShuhao Zhang
Shuhao Zhang
YGYu Guan
Yu Guan
SYShengying Ye
Shengying Ye
SMShu li Man
Shu li Man